Zhang Fen, Chen Yu, Cui Qian, Ge Yan, Liu Yanhui
Department of Pathology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, No. 106, 2nd Zhongshan Road, Guangzhou, 510080, China.
Discov Oncol. 2024 Apr 25;15(1):129. doi: 10.1007/s12672-024-00991-5.
Concurrent follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)was reported in some studies, while the diagnosis of TdT (terminal deoxynucleotydil transferase) positive high grade B cell lymphoma (HGBL) with MYC and BCL2 rearrangements ("double hit") transformed from FL/DLBCL has been rarely reported. Herein, we described the clinical features and mutation profiles of a case diagnosed with TdT positive "double hit" HGBL following the treatment of FL/DLBCL.
This is a 43-year-old Chinese man who was diagnosed with low grade FL (account for 80%) combined with DLBCL (20%) at a stage of IVB. The patient presented with BCL2/IGH translocation without MYC rearrangement, as well as the expressions of CD20, CD19, CD10 and BCL2 at the initial diagnosis of FL/DLBCL. MYC rearrangement and TdT expression occurred after the treatment. The targeted sequencing revealed mutations in KMT2D, FOXO1, CREBBP, ATM, STAT6, BCL7A, DDX3X, MUC4, FGFR3, ARID5B, DDX11 and PRKCSH genes were the co-mutations shared by the FL/DLBCL and TdT positive "double hit" HGBL, while CCND3, BIRC6, ROBO1 and CHEK2 mutations specifically occurred after the treatment. The overall survival time was 37.8 and 17.8 months after the initial diagnosis of FL/DLBCL and TdT positive "double hit" HGBL, respectively.
This study reports a rare case of TdT positive "double hit" HGBL following the treatment of concurrent FL/DLBCL and highlights the mutation characteristics. Collectively, this study will help enrich the knowledge of TdT positive "double hit" HGBL transformed from FL/DLBCL.
一些研究报道了滤泡性淋巴瘤(FL)与弥漫性大B细胞淋巴瘤(DLBCL)并存的情况,而由FL/DLBCL转化而来的伴有MYC和BCL2重排(“双打击”)的末端脱氧核苷酸转移酶(TdT)阳性高级别B细胞淋巴瘤(HGBL)的诊断鲜有报道。在此,我们描述了1例经FL/DLBCL治疗后诊断为TdT阳性“双打击”HGBL的临床特征和突变谱。
这是一名43岁的中国男性,在IVB期被诊断为低级别FL(占80%)合并DLBCL(20%)。患者在FL/DLBCL初诊时表现为BCL2/IGH易位但无MYC重排,以及CD20、CD19、CD10和BCL2的表达。治疗后出现MYC重排和TdT表达。靶向测序显示,KMT2D、FOXO1、CREBBP、ATM、STAT6、BCL7A、DDX3X、MUC4、FGFR3、ARID5B、DDX11和PRKCSH基因的突变是FL/DLBCL和TdT阳性“双打击”HGBL共有的共同突变,而CCND3、BIRC6、ROBO1和CHEK2突变则在治疗后特异性出现。FL/DLBCL和TdT阳性“双打击”HGBL初诊后的总生存时间分别为37.8个月和17.8个月。
本研究报告了1例罕见的经FL/DLBCL治疗后TdT阳性“双打击”HGBL病例,并突出了其突变特征。总体而言,本研究将有助于丰富对由FL/DLBCL转化而来的TdT阳性“双打击”HGBL的认识。